Company Description
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance.
It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration.
The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib.
IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance.
Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot Holding LLC, for prodrug technology development and maintains an exclusive license for IKT-001.
The company was founded in 2008 and is headquartered in Wilmington, Delaware.
| Country | United States |
| Founded | 2008 |
| IPO Date | Dec 23, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 35 |
| CEO | Mark Iwicki |
Contact Details
Address: 1000 N. West Street, Suite 1200 Wilmington, Delaware 19801 United States | |
| Phone | 302 295 3800 |
| Website | inhibikase.com |
Stock Details
| Ticker Symbol | IKT |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $10.00 |
| CIK Code | 1750149 |
| CUSIP Number | 45719W106 |
| ISIN Number | US45719W2052 |
| Employer ID | 26-3407249 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Mark T. Iwicki | Chief Executive Officer and Director |
| Dr. Christopher H. Cabell FACC, M.D. | President, Head of Research and Development and Chief Medical Officer |
| David John McIntyre B.Econs(Acc), BEC, C.P.A., L.L.B., M.B.A. | Chief Financial Officer |
| Dr. John Adams Ph.D. | Chief Scientific Officer |
| Jeffrey J. Kagy | Chief Human Resources Officer |
| Chadwick J. Orevillo MPH | Executive Vice President and Head of Development Operations |
| Timothy J. Pigot | Chief Commercial and Strategy Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 15, 2026 | SCHEDULE 13G/A | Filing |
| May 15, 2026 | SCHEDULE 13G/A | Filing |
| May 15, 2026 | SCHEDULE 13G/A | Filing |
| May 15, 2026 | SCHEDULE 13G/A | Filing |
| May 12, 2026 | 10-Q | Quarterly Report |
| May 12, 2026 | 8-K | Current Report |
| Apr 30, 2026 | ARS | Filing |
| Apr 30, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 30, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 20, 2026 | PRE 14A | Other preliminary proxy statements |